-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

Benzinga·11/15/2024 12:21:15
Listen to the news
Baird analyst Jack Allen maintains MiNK Therapeutics (NASDAQ:INKT) with a Outperform and lowers the price target from $8 to $4.